To confirm the importance of STAT3 in breast cancer stem-like cells, the STAT3 inhibitor, LLL12 [17] (Figure S1), which is a novel analog of a previously reported STAT3 inhibitor LLL3 [18], was used to target STAT3 in breast cancer stem-like cells. This evidence concerns the gene STAT3 and breast carcinoma.